Literature DB >> 10215514

Dynamics of docosahexaenoic acid metabolism in the central nervous system: lack of effect of chronic lithium treatment.

M C Chang1, J M Bell, A D Purdon, E G Chikhale, E Grange.   

Abstract

Using a method and model developed in our laboratory to quantitatively study brain phospholipid metabolism, in vivo rates of incorporation and turnover of docosahexaenoic acid in brain phospholipids were measured in awake rats. The results suggest that docosahexaenoate incorporation and turnover in brain phospholipids are more rapid than previously assumed and that this rapid turnover dilutes tracer specific activity in brain docoshexaenoyl-CoA pool due to release and recycling of unlabeled fatty acid from phospholipid metabolism. Fractional turnover rates for docosahexaenoate within phosphatidylinositol, choline glycerophospholipids, ethanolamine glycerophospholipids and phosphatidylserine were 17.7, 3.1, 1.2, and 0.2 %.h(-1), respectively. Chronic lithium treatment, at a brain level considered to be therapeutic in humans (0.6 micromol.g(-1)), had no effect on turnover of docosahexaenoic acid in individual brain phospholipids. Consistent with previous studies from our laboratory that chronic lithium decreased the turnover of arachidonic acid within brain phospholipids by up to 80% and attenuated brain phospholipase A2 activity, the lack of effect of lithium on docosahexaenoate recycling and turnover suggests that a target for lithium's action is an arachidonic acid-selective phospholipase A2.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10215514     DOI: 10.1023/a:1020989701330

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  43 in total

1.  Stimulation of phospholipase A2 activity in bovine rod outer segments by the beta gamma subunits of transducin and its inhibition by the alpha subunit.

Authors:  C L Jelsema; J Axelrod
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

2.  Changes in cerebral acyl-CoA concentrations following ischemia-reperfusion in awake gerbils.

Authors:  O Rabin; J Deutsch; E Grange; K D Pettigrew; M C Chang; S I Rapoport; A D Purdon
Journal:  J Neurochem       Date:  1997-05       Impact factor: 5.372

Review 3.  Norepinephrine in depressive reactions. A review.

Authors:  W E Bunney; J M Davis
Journal:  Arch Gen Psychiatry       Date:  1965-12

4.  Phospholipase A2 and the hypofrontality hypothesis of schizophrenia.

Authors:  W F Gattaz; J Brunner
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1996-08       Impact factor: 4.006

Review 5.  In vivo imaging of fatty acid incorporation into brain to examine signal transduction and neuroplasticity involving phospholipids.

Authors:  S I Rapoport; D Purdon; H U Shetty; E Grange; Q Smith; C Jones; M C Chang
Journal:  Ann N Y Acad Sci       Date:  1997-05-30       Impact factor: 5.691

6.  Increased platelet phospholipase A2 activity in schizophrenia.

Authors:  W F Gattaz; A Schmitt; A Maras
Journal:  Schizophr Res       Date:  1995-07       Impact factor: 4.939

7.  Incorporation of [1-carbon-11]palmitate in monkey brain using PET.

Authors:  T Arai; S Wakabayashi; M A Channing; B B Dunn; M G Der; J M Bell; P Herscovitch; W C Eckelman; S I Rapoport; M C Chang
Journal:  J Nucl Med       Date:  1995-12       Impact factor: 10.057

Review 8.  A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: review and critical analysis.

Authors:  P J Robinson; J Noronha; J J DeGeorge; L M Freed; T Nariai; S I Rapoport
Journal:  Brain Res Brain Res Rev       Date:  1992 Sep-Dec

9.  Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition.

Authors:  J K Yao; D P van Kammen; J A Welker
Journal:  Schizophr Res       Date:  1994-10       Impact factor: 4.939

10.  Decrease of brain phospholipid synthesis in free-moving n-3 fatty acid deficient rats.

Authors:  N Gazzah; A Gharib; M Croset; P Bobillier; M Lagarde; N Sarda
Journal:  J Neurochem       Date:  1995-02       Impact factor: 5.372

View more
  31 in total

1.  Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism.

Authors:  Sandra Ghelardoni; Richard P Bazinet; Stanley I Rapoport; Francesca Bosetti
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

2.  Kinetics of eicosapentaenoic acid in brain, heart and liver of conscious rats fed a high n-3 PUFA containing diet.

Authors:  Miki Igarashi; Lisa Chang; Kaizong Ma; Stanley I Rapoport
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2013-09-16       Impact factor: 4.006

3.  Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder.

Authors:  Richard P Bazinet; Margaret T Weis; Stanley I Rapoport; Thad A Rosenberger
Journal:  Psychopharmacology (Berl)       Date:  2005-12-13       Impact factor: 4.530

4.  Rat brain docosahexaenoic acid metabolism is not altered by a 6-day intracerebral ventricular infusion of bacterial lipopolysaccharide.

Authors:  Thad A Rosenberger; Nelly E Villacreses; Margaret T Weis; Stanley I Rapoport
Journal:  Neurochem Int       Date:  2009-12-22       Impact factor: 3.921

Review 5.  In vivo fatty acid incorporation into brain phosholipids in relation to plasma availability, signal transduction and membrane remodeling.

Authors:  S I Rapoport
Journal:  J Mol Neurosci       Date:  2001 Apr-Jun       Impact factor: 3.444

6.  Disturbed brain phospholipid and docosahexaenoic acid metabolism in calcium-independent phospholipase A(2)-VIA (iPLA(2)β)-knockout mice.

Authors:  Yewon Cheon; Hyung-Wook Kim; Miki Igarashi; Hiren R Modi; Lisa Chang; Kaizong Ma; Deanna Greenstein; Mary Wohltmann; John Turk; Stanley I Rapoport; Ameer Y Taha
Journal:  Biochim Biophys Acta       Date:  2012-02-10

7.  Dietary n-6 polyunsaturated fatty acid deprivation increases docosahexaenoic acid metabolism in rat brain.

Authors:  Miki Igarashi; Hyung-Wook Kim; Lisa Chang; Kaizong Ma; Stanley I Rapoport
Journal:  J Neurochem       Date:  2012-01-23       Impact factor: 5.372

8.  Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder?

Authors:  H-J Lee; J S Rao; L Chang; S I Rapoport; H-W Kim
Journal:  Mol Psychiatry       Date:  2008-11-04       Impact factor: 15.992

9.  Long-chain omega-3 polyunsaturated fatty acids in the blood of children and adolescents with juvenile bipolar disorder.

Authors:  Edward H Clayton; Tanya L Hanstock; Stephen J Hirneth; Colin J Kable; Manohar L Garg; Philip L Hazell
Journal:  Lipids       Date:  2008-09-10       Impact factor: 1.880

10.  Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: a potential drug for bipolar disorder.

Authors:  Hiren R Modi; Mireille Basselin; Ameer Y Taha; Lei O Li; Rosalind A Coleman; Meir Bialer; Stanley I Rapoport
Journal:  Biochim Biophys Acta       Date:  2013-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.